Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Reinvestment Rate
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Reinvestment Rate of 0.16x as of September 2025, reinvesting ₩426.30 Million (capex ₩213.15 Million plus investments ₩-213.15 Million) from operating cash flow of ₩2.62 Billion. Explore 012790 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sinil Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Also explore 012790 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Sinil Pharmaceutical Co. Ltd. For live market cap and broader valuation context, see Sinil Pharmaceutical Co. Ltd (012790) total market value.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.41x | ₩31.94 Billion | ₩22.69 Billion | ₩8.47 Billion | ▼ -12.0% |
| 2023 | 1.60x | ₩24.24 Billion | ₩15.15 Billion | ₩12.92 Billion | ▼ -9.6% |
| 2022 | 1.77x | ₩24.21 Billion | ₩13.69 Billion | ₩9.33 Billion | ▲ +193.3% |
| 2021 | 0.60x | ₩6.73 Billion | ₩11.16 Billion | ₩3.63 Billion | ▼ -25.7% |
| 2020 | 0.81x | ₩8.98 Billion | ₩11.06 Billion | ₩8.80 Billion | ▲ +1.1% |
| 2019 | 0.80x | ₩9.88 Billion | ₩12.31 Billion | ₩9.73 Billion | ▼ -19.3% |
| 2018 | 1.00x | ₩9.15 Billion | ₩9.19 Billion | ₩8.33 Billion | ▼ -30.2% |
| 2017 | 1.42x | ₩12.36 Billion | ₩8.67 Billion | ₩9.38 Billion | ▲ +315.4% |
| 2016 | 0.34x | ₩4.15 Billion | ₩12.09 Billion | ₩2.57 Billion | ▼ -48.2% |
| 2015 | 0.66x | ₩6.34 Billion | ₩9.56 Billion | ₩5.80 Billion | ▼ -19.7% |
| 2014 | 0.83x | ₩7.70 Billion | ₩9.33 Billion | ₩2.24 Billion | — |